Sitagliptin - Enhancing incretin action

British Journal of Diabetes and Vascular Disease

Volumn 7, Issue 3, 2007, Pages 134-139

  Campbell, Ian W ^a   Day, Caroline ^b  

^a VICTORIA HOSPITAL   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

DPP 4; Gliptin; Incretin; Inhibitor; Sitagliptin; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RHINOPHARYNGITIS; WEIGHT CONTROL; WEIGHT GAIN;

EID: 34547799011     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514070070030601     Document Type: Article

References (27)

1. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pep 2005;128:87-91.
2. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-21.
3. Elrick H, Stimmler L, Hlad C J, Arai Y. Plasma insulin responses to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.
4. Unger RH, Eisentraut AM. Entero-insular axis. Arch Int Med 1969; 123:261-6.
5. Marks V, Morgan L. The entero-insular axis in Recent advances in diabetes, Nattrass M, Santiago (eds) Churchill Livingstone, London 1984;1:55-71.
6. Nauck M, Stockmann F, Ebert R, Creuzfeldt W. Reduced incretin effecting type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52.
7. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 1993;91:301-07.
8. Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006;12:1731-50.
9. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006;3:153-65.
10. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117:24-32.
11. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase 4 (DPP 4) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes Vasc Dis Res 2006;3:159-65.
12. Bailey CJ. Oral antidiabetic drugs. Encyclopedia of Molecular Pharmacology Offermans S, Rosenthal W (eds) Springer (in press).
13. Sitagliptin, Summary of Product Characteristics http://emc.medicines.org.uk/
14. Herman G, Bergman A, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia 2006;49:(suppl 1) Abstract 0795.
15. Hermann G, Hanefeld M, Wu M et al. Effect of MK-0431, a dipeptidyl peptidase 4 (DPP-4) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 2005;54:Abstract 541-P.
16. Nonaka K, Kakikawa T, Saro et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes. Diabetologia 2006; 49(suppl1):Abstract 0038.
17. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of sitagliptin over 18 weeks in patients with type 2 diabetes. Diabetologia 2006;49:(suppl 1).Abstract 0794.
18. Aschner P, Kipnes M, Lunceford J et al. Effect of the dipeptidyl peptidase-4 sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7.
19. Goldstein BJ, Feinglos MN, Lunceford et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care (in press), published online May 7 2007.
20. Rosenstock J, Brazg R, Andryuk P et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglita-zone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Therapeutics 2006;28: 1556-68.
21. Nauck MA, Meininger G, Sheng D et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205.
22. Charbonnel B, Karisik A, Liu J et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
23. Brazg R, Xu L, Dalla Man C et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and b-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93.
24. Nathan DM, Buse JB, Davidson ME et al. Management of hyperlgycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006;29:1963-72.
25. Mistry G, Bergman A, Wen-Lin L et al. Effects of sitagliptin on the pharmacokinetics (PK) of rosiglitazone in healthy subjects. Diabetes 2006; Abstract 2001-PO.
26. Ruddy MK, Bergman AJ, Zheng W et al. Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea, glyburide. Diabetes 2006.Abstract 558-R
27. Vilsboll T, Knop FK. DPP 4 inhibitors current evidence and future directions. Br J Diabetes Vasc Dis 2007;2:69-74.